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Abstract: The study objective was to determine the mechanical integrity and radiopacity
of regenerated bone within critical-sized defects (CSDs) in radii of rabbits using recombinant human bone morphogenetic protein 2 (rhBMP-2) with a porous, biodegradable
poly( D ,L-lactic acid) (PDLLA) carrier (designated PLA). Twenty millimeter, unilateral
radial ostectomies were created in 96 skeletally mature New Zealand white rabbits. The
rabbits were randomly assigned to six treatment groups with two euthanasia periods.
Treatment groups included unfilled defect (n Å 8), segmental autograft (n Å 8), PLA /
0 mg rhBMP-2 (n Å 8), PLA / 17 mg rhBMP-2 (n Å 8), PLA / 35 mg rhBMP-2 (n Å
8), and PLA / 70 mg rhBMP-2 (n Å 8). The radiopacity was significantly greater for
the 35- and 70-mg rhBMP-2 groups at 4 weeks compared to unfilled controls, PLA only,
and 17-mg rhBMP-2 groups and equivalent to the autograft. At 8 weeks all groups receiving rhBMP-2 were equivalent to the autograft and significantly greater than unfilled
defects and PLA alone. Similarly, the biomechanical analysis indicated significantly
greater torque at failure for the 35-mg rhBMP-2 group compared to all other groups at
4 weeks. By 8 weeks all groups receiving rhBMP-2 and autograft had significantly greater
torque than unfilled controls and PLA alone. These radiomorphometric and biomechanical results indicate PLA may be a suitable carrier for rhBMP-2 used for skeletal regeneration.
Keywords: bone morphogenetic protein; bone regeneration; critical size defect; rabbit;
biomechanics

INTRODUCTION

Bone grafts have been used for decades to repair osseous
discontinuities resulting from trauma, neoplasm resection,
and congenital abnormalities; and over 100 000 are performed each year in the United States.1,2 Autografts are
most widely used by surgeons. These grafts contain viable
cells, bone marrow containing osteoprogenitor cells, and a
collagenous matrix that combine to form a favorable milieu
for osteogenesis, osteoinduction, and osteoconduction. The
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major disadvantages of autografts are donor site morbidity
and limitations on the quantity of graft material.1,3,4 Allografts are often considered as an alternative to autografts.
Although allografts do not contain viable cells at the time
of implantation, they serve as a scaffolding for revascularization and as a source for healing factors promoting osseous ingrowth (i.e., osteoconduction). However, allografts
have been associated with disease transmission and infections.1,5 – 7 Additionally, common problems with allografts
include nonunions and delayed unions.1,8 Gross et al.9 reported incomplete incorporation of allografts even as late
as 7 years. Neither autograft nor allograft provide the patient with ideal bone graft material. Consequently, there is
a strong clinical need to develop alternatives to autografts
and allografts.1,2 Hydroxyapatite (HA), tricalcium phosphate, and bioactive glasses have proven to be viable bone
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Figure 1. A graphical representation of the temporal changes and comparative changes in radiopacity
between treatment groups in the regenerating rabbit radii. The autograft and all rhBMP-2 filled defects
produced significantly more bone than unfilled defects and PLA-only groups by 4 weeks. The radiopacity measurements represent the mean of eight animals for each treatment group. A, unfilled defect;
B, segmental autograft; C, PLA only; D, 17 mg rhBMP-2 / PLA; E, 35 mg rhBMP-2 / PLA; F, 70 mg
rhBMP-2 / PLA. (*) B, D, E, F ú A, C ( p õ 0.05). (**) B ú A, C, D, E, F (p õ 0.05).

graft substitutes.10 – 16 These alloplastic materials vary in
porosity, granularity, size, and resorbability and typically
serve as a template or scaffold for osteoconduction within
the bony defect. More recently, recombinant genetically
engineered bone growth proteins, such as bone morphogenetic proteins (BMPs) and transforming growth factor
b(TGFb ), were combined either with bioresorbable polymers or calcium phosphate carriers and emerged as an
effective and promising osteoinductive bone graft alternative.17 – 20 Animal studies validated the efficacy and safety
of BMPs in regenerating non-load-bearing skeletal defects.18,21 – 24 However, delivering the protein to skeletal defect sites through use of an appropriate carrier has been a
challenging task. The most common BMP carriers investigated include collagen sponges 21,22 and biodegradable
polymers.25,26 This study will use a biodegradable polymer
[poly( D,L lactic acid) (PDLLA) referred to as recombinant
human BMP-2 (rhBMP-2) / PLA] adsorbed with rhBMP2 as a potential bone graft. Therefore, the purpose of this
study was threefold: to regenerate critical-sized defects
(CSDs) in radii of rabbits with several varying doses of
rhBMP-2 / PLA, to assess radiographic density and me/
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chanical integrity of the regenerated bone, and to compare
the rhBMP-2 regenerated bone to that of unfilled defects
and autograft-filled defects. The hypotheses of the study
were that one of the doses of rhBMP-2 / PLA would
promote radiographic density similar to that of the ‘‘gold
standard’’ autograft and the biofunctionality promoted by
one of the rhBMP-2 doses would be equivalent to that
promoted by the autograft.

MATERIALS AND METHODS

Ninety-six skeletally mature New Zealand white rabbits
were randomly assigned to six treatments groups and two
euthanasia periods (4 and 8 weeks). Treatment groups
included
1.
2.
3.
4.
jbma

unfilled defect (n Å 8),
segmental autograft (n Å 8),
PLA / 0 mg rhBMP-2 (n Å 8),
PLA / 17 mg rhBMP-2 (n Å 8),
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Figure 2. Photographs illustrating changes in radiopacity between
treatment groups at 8 weeks including the unfilled defect (CSD),
segmental autograft, 0 mg rhBMP-2 / PLA, 17 mg rhBMP-2 / PLA,
35 mg rhBMP-2 / PLA, and 70 mg rhBMP-2 / PLA.

5. PLA / 35 mg rhBMP-2 (n Å 8), and
6. PLA / 70 mg rhBMP-2 (n Å 8).
The PLA carrier used for rhBMP-2 was PDLLA.
PDLLA was designed with high porosity to enhance
adsorption of rhBMP-2 within the macrostructure.27 The
polymer was manufactured into cylindrical formats (4.68
1 20 mm). Highly purified rhBMP-2 18,28 was placed in
sterile glass vials containing a sodium glutamate buffer (5
mM, pH 4.5). At the time of surgery, 0.17 mL of buffer
containing either 0, 17, 35, or 70 mg of rhBMP-2 was
transferred in a sterile fashion by syringe to the sterile PLA
delivery vehicle.29 Immediately following the transfer of
the growth factor the rhBMP-2 / PLA was placed into the
ostectomy gap.
The rabbits were anesthetized using a mixture of 10 mL
of ketamine hydrochloride (Ketaset, USP, 100 mg/mL,
Fort Dodge Laboratories, Inc., Fort Dodge, IA) and 5 mL
of xylazine (Gemini SA, 20 mg/mL, Burns Veterinary Supply, Inc., Rockville Center, NY) at a dose of 0.65 mL/kg
body weight. Triple antibiotic opthalmic ointment (Lacrilube, Allergen Pharmaceuticals, Irvine, CA) was applied
to the rabbit’s eyes when anesthesized to prevent dryness.
Prophylatic antibiotics (Baytril, Miles Inc., Shawnee Mission, KS) were administered preoperatively at a dose of
2.25 to 2.50 mg/kg. The operative site (the left or right
front limb) was shaved, prepped, and draped for aseptic
surgery with the rabbit in the supine position. A tourniquet
was placed around the axillary region. The subcutaneous
region around the operative site was injected with 0.5 mL
of 2% Lidocaine with epinephrine 1:100,000 (Xylocaine,
20 mg/mL, Astra Pharmaceutical Products Inc., Westborough, MA). An approximately 3-cm long superiomedial
/
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incision was made and the tissues overlying the distal diaphyseal radius were dissected. A 2-cm segmental defect
was created in the radius with a mini-oscillating saw using
copious sterile saline irrigation. The assigned treatment material was placed in the bony defect. No internal fixation
was supplied because of the stabilization of the adjacent
ulna. The soft tissues were closed in layers using 4-0 Vicryl
sutures (Ethicon Inc., Somerville, NJ). The skin was closed
with surgical staples (Precise DS-25, 3M, St. Paul, MN).
Postoperative analgesia (Buprenex, 0.3 mg/mL, Reckitt
and Coleman Pharmaceuticals Inc., Richmond, VA) was
given as needed at a dose of 0.1 mL/kg. Water and food
were provided ad libidum.
Immediate postoperative lateral radiographs were taken
of the operative limb. Standardized radiographs were taken
immediately postoperatively, every 2 weeks in life, and at
sacrifice.
At sacrifice, the radius–ulna complex was disarticulated
at the elbow and wrist and specimens were stored at 020
⬚C with tissue intact until torsional mechanical testing was
initiated. Torsional tests were preferable to bending tests
in this animal model in that they simulate clinically relevant
fracture patterns, apply equal loads to all sections of the
bone, and are relatively insensitive to specimen length and
orientation.30,31 Bone fails in torsion at the weakest point
along the shaft.
Specimens were thawed to room temperature, the soft
tissue was carefully removed, and the proximal and distal
ends of the radius–ulna complex were potted in dental
plaster (0-67 Snow White Stone, Miles Inc., South Bend,
IN) in order to grip the specimen for testing. Transcortical
cuts were made in the ulna adjacent to the potted ends to
eliminate the mechanical contribution of the ulna and isolate the radius during torsional testing. Separation of the
ulna from the radius was not possible due to ulnar hypertrophy, scar tissue formation, and fibrous fusion. Unpublished
preliminary experimentation indicates the discontinuous
ulna segment does not affect the breaking torque or stiffness. The radius of the specimens was loaded to failure in
torsion using a biaxial MTS MiniBionix materials testing
machine (MTS Inc., Minneapolis, MN) at a loading rate
of 180⬚ /s.32 Data were collected at 1000 Hz for the duration
of the test. Values of ultimate torque (torque at failure)
and angular displacement at failure were extracted from
the data. Specimen stiffness and energy absorbed during
failure were calculated as the slope of the torque/angle
curve and the area under the torque/angle curve, respectively.
The biomechanical and radiomorphometric results were
analyzed using a 2-way analysis of variance (ANOVA) to
look at the effects of time (4 and 8 weeks) and treatment
(A, B, C, D, E, and F). If significance was noted with the
ANOVA, a 1-way ANOVA was used to look at the effects
of time by treatment and treatment by time followed by a
Duncan’s multiple comparison procedure with a significance level set at p Å 0.05. Given the sample size, the
jbma
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Figure 3. Graphical representation of the breaking torque of the regenerating radii at 4 and 8 weeks.
The 35-mg rhBMP-2 was significantly greater than all other treatments at 4 weeks, yet by 8 weeks
the autograft and all BMP-2 treated groups were equivalent. The breaking torque measurements
represent the mean of eight animals for each treatment group. A, unfilled defect; B, segmental
autograft; C, PLA only; D, 17 mg rhBMP-2 / PLA; E, 35 mg rhBMP-2 / PLA; F, 70 mg rhBMP-2 /
PLA. (*) E ú A, B, C, D, F (p õ 0.05). (**) B, D, E, F ú A, C ( p õ 0.05).

statistical power of the analysis was 80% (SAS, Inc., Version 6.11, Cary, NC).

RESULTS
Radiomorphometry

Radiomorphometric analysis indicated the unfilled defect
(group A) displayed radiolucent nonunion throughout the
8-week study. Autograft sites revealed a radiolucent interface bracketing the graft at 4 weeks that was less evident
by 8 weeks. A slight radiopacity proximal and distal to a
radiolucent midportion was observed for the unfilled defects (group A) and the 0-mg rhBMP-2 / PLA cohort
(group C) at 4 and 8 weeks. The autograft and all rhBMP2 filled defects (groups B, D, E, and F) produced equivalent
amounts of regenerated bone by 4 weeks that was significantly more bone than the unfilled defects and PLA-only
groups (groups A and C) (p õ 0.05). The same pattern
/
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(B, D, E, F ú A, C) was observed at 8 weeks (Fig. 1).
All rhBMP-2 treated and autograft treated wounds revealed
complete bridging and complete radiopacity of the bridging
tissue by 8 weeks. A time-dependent effect was noted in
the increase of opacity between the 2-week measurement
and the 4-, 6-, and 8-week measurement for the autograft
and all rhBMP-2 groups (groups B, D, E, and F) (p õ
0.05). The unfilled defect and PLA-only group (groups A
and C) did not exhibit more opacity with time. The temporal changes in radiopacity can be visualized in the graph
of Figure 1 and the composite radiographs of Figure 2.
PLA is radiolucent; therefore, the radiopacity of all groups
except the segmental autograph group (group B) were
equivalent immediately postsurgery. At 2 weeks the 35and 70-mg rhBMP-2 groups (groups E and F) portrayed a
hint of radiopacity that increased and was equivalent to the
autograft (group B) by 4 weeks. At 6 weeks the highest
doses of rhBMP-2 (groups E and F) portrayed a bonelike
radiographic quality, yet by 8 weeks complete bridging
jbma
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Figure 4. Maximum angular displacement at failure of the regenerating radii at 4 and 8 weeks. All
treatment groups were equivalent at 4 weeks. Yet, by 8 weeks the angular displacement of the PLAonly group was significantly greater than other groups. The angular displacement measurements
represent the mean of eight animals for each treatment group. A, unfilled defect; B, segmental
autograft; C, PLA only; D, 17 mg rhBMP-2 / PLA; E, 35 mg rhBMP-2 / PLA; F, 70 mg rhBMP-2 /
PLA. (*) C ú A, B, D, E, F (p õ 0.05).

was noted including cortical development. Groups A, C,
D, E, and F were noted to have fringes of radiopacity that
were localized near the host bone junction with no isolated
radiopaque areas distant from the host bone.
Biomechanics

The failure torque was significantly greater for the 35-mg
BMP treated animals (group E) than for all other treatments at 4 weeks. By 8 weeks the autograft (group B) and
all BMP treated animals (groups D, E, and F) had equivalent breaking torque, yet the unfilled defects and PLA-only
defects (groups A and C) were significantly weaker
(Fig. 3).
The angular displacement at failure was not different
among the groups at 4 weeks. Yet by 8 weeks the angular
displacement of the PLA only (group C) was significantly
greater than all other groups (Fig. 4).
The mechanical stiffness of the defects at 4 weeks was
equivalent for all rhBMP-2 treated groups (groups D, E,
/
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and F) and the autograft group (group B) and significantly
greater than the unfilled defects and PLA-only groups
(groups A and C). Although the magnitude of stiffness
was greater at 8 weeks for all groups, the same trends were
noted (Fig. 5).
The energy absorbed at failure was significantly greater
for the 35-mg rhBMP-2 / PLA group (group E) than all
other groups at 4 weeks but not greater than the autograftfilled defects (group B) (p õ 0.05). However, by 8 weeks
the energy to failure for the autograft group (group B) was
significantly greater than all other groups. (Fig. 6).

DISCUSSION

The results of this radiomorphometric and biomechanical
study concur with our hypothesis: all doses (17, 35, and
70 mg rhBMP-2), used in conjunction with a PLA carrier,
were able to regenerate bone in a rabbit radius CSD with
comparable mechanical strength and radiopacity to autojbma
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Figure 5. Mechanical stiffness of the regenerating radii at 4 and 8 weeks. At both 4 and 8 weeks,
all rhBMP-2 treated groups and autograft had significantly greater stiffness than unfilled defects and
PLA-only groups. The stiffness measurements represent the mean of eight animals for each treatment
group. A, unfilled defect; B, segmental autograft; C, PLA only; D, 17 mg rhBMP-2 / PLA; E, 35 mg
rhBMP-2 / PLA; F, 70 mg rhBMP-2 / PLA. (*) B, D, E, F ú A, C ( p õ 0.05).

graft-filled defects within 4 weeks of surgery. The rhBMP2 augmented defects healed significantly better than unfilled defects or defects filled with only PLA. There was a
dose–response relationship of rhBMP-2 for radiopacity at
2 weeks, and the higher doses produced superior bone formation than the lowest dose. The results of this biomechanical study support our previously reported quantitative histomorphological findings indicating that rhBMP-2 and
PLA carrier can effectively regenerate bone in a dose–
response fashion at specific skeletal sites (rabbit radius).29
The classic dose–response relationship was observed
radiographically and biomechanically in rhBMP-2 treated
animals, especially at later time points. At early time points
the response was more variable. The actions of BMP are
receptor mediated that would theoretically lead to a standard dose–response curve (plateau in response once the
receptors are saturated). The temporal aspect of this study
complicates the dose–response mechanism. In this in vivo
bone regeneration system, BMP also has autocrine and
paracrine functional components. The transient disparity
/
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between the 35- and 70-mg rhBMP-2 groups at 4 weeks
seen in the biomechanical data, and to a lesser extent in
the radiographic data, may simply be a stabilization process
of the physiological system. At the later time points, 6 and 8
weeks for radiographic data and 8 weeks for biomechanical
data, the data follows classic dose–response behavior. In
a separate experiment, a similar rhBMP-2 dose–response
was observed in the quantity of bone within the defect site
that was assessed histologically.29
The rhBMP-2 / PLA animals exhibited a significant
time-dependent increase in bone formation (radiopacity)
within the gap between 2 and 4 weeks. After 4 weeks no
significant increase in bone within the defect was radiographically noted for any experimental groups. This would
indicate that rhBMP-2 effects are seen immediately by
stimulating early bone regeneration. The effects of local
administration of rhBMP-2 would tend to diminish with
dissolution of rhBMP-2 concentration at the defect site.
Although the mechanical strength at 2 weeks was not evaluated, it would be estimated to parallel the increase in radiojbma
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Figure 6. Energy absorbed at failure of the regenerating radii at 4 and 8 weeks. The 35-mg rhBMP2 group had significantly higher energies at failure than all other treatment groups at 4 weeks except
the autograft group. However, by 8 weeks the autograft group had higher energies than all other
treatment groups. The energy measurements represent the mean of eight animals for each treatment
group. A, unfilled defect; B, segmental autograft; C, PLA only; D, 17 mg rhBMP-2 / PLA; E, 35 mg
rhBMP-2 / PLA; F, 70 mg rhBMP-2 / PLA. (*) E, B ú A, C, D, F ( p õ 0.05). (**) B ú A, C, D, E, F
(p õ 0.05).

pacity. Histological assessment of bone formation rates
within the defect site would also confirm the time-dependent effects of rhBMP-2 noted radiographically and is
planned for follow-up studies.
Although the use of rhBMPs for bone regeneration and
developmental biology have been studied extensively, 24,33
the use of PDLLA as a carrier for growth factors and/
or an osteoconductive template has not been previously
investigated. An appropriate delivery system is crucial to
the overall effectiveness of the administered growth factor.
The delivery system is responsible for the localization of
the growth factor, mesenchymal cell deposition and retainment, and establishment of a template for contour and
structural confinement of new bone growth.
In previous studies two classes of delivery systems for
rhBMPs were used: collagen based and poly( a-hydroxy
acids).21,22 HA, HA-tricalcium phosphate, and demineralized bone matrix were also used to deliver rhBMPs.16,18
Calcium phosphate delivery systems are either not biodegradable or do not biodegrade at the same rate at which
/
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bone is formed and therefore would have limited clinical
utility. Demineralized bone matrix produced inconsistent
clinical results due to infection, immunologic rejection,
viral transmission, varying processing techniques and sterilization, and lack of continuity and structural integrity.34,35
There has been controversy over the biocompatibility and
use of poly(lactic acid) and poly(glycolic acid) within
skeletal defects.36,37 However, the material characteristics
of these polymers holds great potential for use in skeletal
regeneration, specifically their ability to degrade in a reproducible and designated fashion (given the molecular weight
of polymeric components) with the potential for drug delivery release with degradation. The polymer used for this
project, PDLLA (designated PLA) was custom designed
to have specific characteristics of degradation kinetics to
release rhBMP-2, which coincided with tissue regeneration
within the defect.38
The mechanical strength of regenerated bone using polymer carriers and rhBMP-2 was recently published by Bostrom et al.39 Bostrom and colleagues evaluated rhBMP-2
jbma
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combined with polylactic glycolic acid porous microspheres and autologous blood in healing of a 2-cm ulnar
defects in New Zealand white rabbits. They found a similar
dose-dependent relationship as the current study between
the dose of rhBMP-2 and the mechanical strength of the
healed defects. Additionally, the optimal rhBMP-2 dose
(35–40 mg rhBMP-2) for bone regeneration concurs between the two studies. Both studies indicate that at this
optimal dose of rhBMP-2, bone strength returned to normal
(intact limb) by 8 weeks.
Other studies evaluated the strength of demineralized
bone matrix and rhBMP-induced bone within defects using
collagenous carriers.40,41 Bolander and Balian found demineralized bone matrix induced active woven bone formation
within large ulnar defects in rabbits, yet the strength of the
newly formed bone was 50% that of intact bone after 12
weeks.40 Cook et al.41 used rhOP-1 (rhBMP-7) with a collagen carrier to fill ulnar defects in rabbits. At 8 weeks postoperatively new bone had formed within the defect sites
with primarily lamellar bone. Additionally, the torsional
strength of the ulnae were comparable to the strength of
the intact ulna after 12 weeks. The results of Cook et al.41
using rhBMP-7 with a collagen carrier are similar to those
of Bostrom et al.39 and the current study using rhBMP-2
with a polymer carrier. The local administration of rhBMP
unequivocally improves bone healing of large defects compared to autograft, allograft, and demineralized bone matrix
in laboratory animals. Additionally, the new bone formed
within the defect achieves the mechanical strength of intact
established bone.
In summary, this study showed that PDLLA provides a
viable osteoconductive matrix for infiltration of new bone
and a means to deliver rhBMP-2 to the defect site. It assembles a mechanically robust construct within 4 weeks of
application within a rabbit radius CSD. The use of rhBMP
with a polymer carrier provides a viable option for the
repair of bony defects while eliminating immunogenic and
donor site morbidity associated with standard graft materials (i.e., collagen, demineralized bone, autograft, and allograft). The robust mechanical strength demonstrated by
the regenerated bone matrix produced in the rhBMP-2 /
PLA composite makes this graft substitute a potential future option for many orthopedic procedures, including repair of large segmental bone defects as a result of trauma,
neoplasia, or infection. It may also be applicable in prosthetic fixation, spinal arthrodesis, and fracture fixation.
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